Takeda bowel drug gets US panel support despite brain disease debate
This article was originally published in Scrip
Executive Summary
Takeda Pharmaceutical’s experimental drug vedolizumab should be approved for use in the US for a pair of severe bowel disorders, a panel of FDA advisers decided after a daylong session discussing the therapy's benefit and possible risk of a rare and lethal brain disease.